Don Soland

Don Soland

Plus aucun poste en cours

Fortune : 953 928 $ au 31/05/2026

67 ans
Health Technology
Consumer Services

Profil

Daniel B. Soland was Director-Worldwide Marketing Operations & VP at Corixa Corp.
from 1993 to 2002.
Served as President & Chief Executive Officer at Epigenesis Pharmaceuticals LLC from 2002 to 2005.
Held the position of President at Seqirus Vaccines Ltd. from 2005 to 2006.
Was President-Chiron Vaccines at Chiron Corp.
from 2005 to 2006.
Chief Operating Officer & Senior Vice President at Viropharma, Inc. from 2008 to 2014.
Chief Operating Officer & Senior Vice President at Shire ViroPharma, Inc. from 2008 to 2014.
Chief Executive Officer & Executive Director at uniQure NV in 2016.
Independent Director at ACADIA Pharmaceuticals, Inc. from 2015 to 2025.
Independent Director at DBV Technologies SA from 2015 to 2025.
Non-Executive Director at Oxford Biomedica Plc from 2015 to 2016.
Independent Director at KalVista Pharmaceuticals, Inc. from 2019 to 2022.
Chief Operating Officer & Senior Vice President at Idera Pharmaceuticals, Inc. from 2020 to 2022.
Director at Tarsa Therapeutics, Inc. Education includes undergraduate studies at the University of Iowa.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
29/05/2025 44 041 ( 0,03% ) 953 928 $ 31/05/2026

Anciens postes connus de Don Soland

SociétésPosteFin
ACADIA PHARMACEUTICALS INC. Directeur/Membre du Conseil 30/10/2025
DBV TECHNOLOGIES Directeur/Membre du Conseil 18/09/2025
Directeur des opérations 28/09/2022
KALVISTA PHARMACEUTICALS, INC. Directeur/Membre du Conseil 26/05/2022
UNIQURE N.V. Directeur Général 22/09/2016
Voir l'expérience en détail de Don Soland

Formation de Don Soland

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

59

Relations au 1er degré

14

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées14

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Viropharma, Inc.

  1. Bourse
  2. Insiders
  3. Don Soland
- 40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !
j
:
:
PROFITEZ-EN MAINTENANT